Our study has generated much interest in #Luxturna #genetherapy #healtheconomics…
[ad_1]
Our study has generated much interest in #Luxturna #genetherapy #healtheconomics: Cost-effectiveness of Voretigene Neparvovec-rzyl vs Standard Care for RPE65-Mediated Retinal Disease https://t.co/3DeMpzCgRq via @JAMAOphth part of @JAMANetwork
[ad_2]
Source by Thomas Ciulla, MD, MBA